High purity TAF Tenofovir Alafenamide Hemifumarate TAF in bulk supplyCheap TAF in stock

Min.Order / FOB Price:Get Latest Price

1 Kilogram	Negotiable

1 Kilogram

Negotiable

Min.Order :1 Kilogram
Purity: 98.0%~102.0% (on the anhydrous basis)
Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

High purity TAF Tenofovir Alafenamide Hemifumarate TAF in bulk supply Cheap TAF in stock

Quick Details

Appearance:White to off white powder.
Application:HIV, HBV
PackAge:Two-layer LDPE bag and All Paper Barrel.
ProductionCapacity:10|Metric Ton|Year
Storage:2~8°C
Transportation:as per request

Superiority:

High purity TAF Cheap TAF in stock

Tenofovir Alafenamide Hemifumarate TAF in bulk supply

LONZEAL Pharmaceuticals was founded in 2006 and has become a leading manufacturing company covering finished formulation, active pharmaceutical ingredients and advanced intermediates, where ICH guidelines have been strictly applied in the whole chain of R&D, manufacturing process and quality management.

LONZEAL is taking attentiveness and profession to build high quality products, and contributing to health and beautiful life for everyone in the world. The products and manufacturing site of Lonzeal have been approved and inspected by stringent drug authorities such as USFDA, WHO, China NMPA, Brazil ANVISIA and India DCGI, based on which, we have been supplying to esteemed customers globally in the past 15 years with regulatory compliance and good quality.

We have manufacturing site located in Hebei National Biomedical Industrial Zone, FPPs and APIs R&D Center of in Shijiazhuang Hi-tech Development Park, and the commercial office in Beijing, China.

Our current main products cover anti-virus, anti-depression and anti-neuropathic pain areas. Lonzeal has become one of the key manufacturers in the global supply of anti-HIV drugs and is providing support to the treatment need of over 4 Million patients each year worldwide.

role

Tenofovir alafenamide (TAF), an oral nucleoside transcriptase inhibitor developed by Gilead, is another prodrug of tenofovir disoproxil fumarate (TDF), developed for hepatitis B virus infection (HBV) and acquired immune syndrome (HIV).

use

Tenofovir alafine fumarate can be used as a solvent, catalyst for alkylation, esterification and polymerization reactions. 99% of the products are mainly used in medicine, 70% of the products are mainly used in electroplating industry. Nutritional drugs, combined with a low-protein diet, are the core drugs for the prevention and treatment of damage caused by protein metabolism disorder caused by chronic renal insufficiency, chronic renal insufficiency and wasting malnutrition.

Details:

A new drug called Tenofovir Alafenamide Fumarate, or TAF, has been coming into the spotlight in recent years, with the development of antiviral drugs to treat chronic hepatitis B. The drug is an upgrade of Tenofovir Disoprox, or TDF, an oral antiviral drug already on the market.

In clinical trials, on behalf of Norfolk WeiYi phenol amine fumaric acid has been shown in dose is only one over ten of tenofovir ester doses, it has a very high antiviral properties, resistance to like tenofovir ester is very low, at the same time compared to the drug tenofovir ester has better security, to the kidney and bone fewer side effects.

Like Adefovir dipivoxil and Tenofovir dipivoxil, tenofovir dipivoxil is a nucleotide drug that was developed and patented by Gilead Sciences. Tenofovir alafenamide fumaric acid is marketed as Vemlidy.

On November 10, 2016, the U.S. Food and Drug Administration (FDA) approved tenofovir alafialamine fumaric acid for the treatment of chronic hepatitis B in the United States.

On 19 December 2016, Japan's Ministry of Health, Labour and Welfare (MHLW) approved tenofovir alafenamide fumaric acid for the treatment of chronic hepatitis B in Japan.

On 1 September 2017, the European Medicines Agency (EMA) approved tenofovir alafialamine fumaric acid for the treatment of chronic hepatitis B in eu member states.

View All

Visit Store